Option chain shows key data for Ensysce Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ensysce Biosciences.

Ensysce Biosciences (NASDAQ:ENSC) Stock, Option Chain

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Lyft App

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APPS

ARBB

ATCH

BROS

CDLX

CRSR

ENSC

FOXO

FRSH

LYFT

MDJH

MTCH

SEDG

STRO

TRNR

WOLF

Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket

Carvana

ATEC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

CALC

CPSH

CVNA

DAWN

EFSH

ELAB

LUXH

RDDT

RELY

ROKU

ROOT

Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Wall-Street-dall

Earnings

Equities

Eurozone

Commodities

Intraday Update

APDN

GOOG

GOOGL

SVMH

THAR

Dow Surges Over 150 Points; Alphabet Posts Upbeat Results

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

<p><strong>First Quarter and Full Year Fiscal 2025 Outlook</strong></p>
<p>For the fiscal quarter ending December 31, 2024, revenue is expected to be in the range of $47 million to $50 million. GAAP net loss is expected to be in the range of ($26) million to ($23) million. Adjusted EBITDA is expected to be in the range of ($9) million to ($6) million.</p>
<p>For the full fiscal year ending September 30, 2025, the company expects revenue to be in the range of $236 million to $247 million which includes an estimated $20 million of fixed contracts at the mid-point of guidance. GAAP net loss is expected to be in the range of ($40) million to ($29) million. Adjusted EBITDA is expected to be in the range of $15 million to $26 million.</p>


Guidance

CRNC

Cerence Expects Q1 Revenue Of $47M-$50M Vs $47.65M Est, FY25 Revenue Of $236M-$247M Vs $324.34M Est

<p>Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells.</p>
<p>The new HFE arrays utilize a flexible polymer material in place of the ceramic discs used in the current Optune Gio arrays, making them one-third lighter and 50% thinner.</p>


Biotech

Health Care

General

NVCR

The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of 2025 Through A Controlled Transition Plan

Interactive Strength  Board Approves Maximum Cumulative Bitcoin Purchase Of Up To $5M;  Plans To Accept Payment In Digital Currencies

CATO

Cato Q3 EPS $(0.79) Down From $(0.30) YoY, Sales $144.6M Down From $156.7M YoY

<p>UBS  analyst A.J. Rice   initiates coverage on Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Buy rating and announces Price Target of $175.</p>


Price Target

Initiation

Analyst Ratings

ENSG

UBS Initiates Coverage On Ensign Group with Buy Rating, Announces Price Target of $175

<p>Wedbush  analyst Nick Setyan   reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Outperform and maintains $50 price target.</p>


Reiteration

JACK

Wedbush Reiterates Outperform on Jack In The Box, Maintains $50 Price Target

<p>Benjamin Kovler, Chairman and Interim Chief Executive Officer, participated in the private placement to purchase 10,000 shares of common stock at a purchase price of $38.76.</p>


Financing

AGFY

Agrify Announced A Non-brokered Private Placement Priced At $22.30 Per Share For Aggregate Proceeds Of Approximately $25.9M

<p>Company Outlook &amp; Summary</p>
<p>Net income attributable to Deere&nbsp;&amp; Company for fiscal 2025 is forecasted to be in a range of $5.0&nbsp;billion to $5.5 billion.</p>
<p>"As we navigate ongoing headwinds across our markets, we remain committed to making meaningful investments in our future while deepening our relationships with customers," May continued. "Our team of over 75,000 dedicated employees come to work each day with a singular focus: delivering products and solutions that enhance efficiency and reduce operating costs for our customers. By providing the essential tools they need, we empower our customers to succeed and thrive in an ever-evolving and challenging landscape."</p>


Deere & Company Projects Fiscal 2025 Net Income Between $5B-$5.5B

<p>VSE plans to add an additional 110 new employees over the next five years, supporting the existing base of approximately 250 South Florida based employees.&nbsp;</p>
<p>The Company also intends to invest approximately $3.5 million in tenant improvements, including new offices, additional MRO capabilities, a training and conference center, and renovations to existing spaces.</p>


VSEC

VSE Plans Relocation Of Its Corporate Headquarters To Miramar, Florida

Earnings Beats

Cerence Q4 2024 Adj. EPS $(0.07) Beats $(0.36) Estimate, Sales $54.805M Beat $47.650M Estimate

<p>Across the recent three months, 31 analysts have shared their insights on Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $412.39, a high estimate of $505.00, and a low estimate of $300.00. Experiencing a 8.71% decline, the current average is now lower than the previous average price target of $451.72. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732190443_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Ulta Beauty among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$472.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$380.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$395.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$357.00</td>
<td>$356.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$435.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$424.00</td>
<td>$426.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$390.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$395.00</td>
<td>-</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Sell</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$450.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$435.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Kelly Crago</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$345.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$442.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$335.00</td>
<td>$328.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$505.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$385.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$356.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$385.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$395.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$435.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$420.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$448.00</td>
<td>$552.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$522.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$430.00</td>
<td>$500.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ulta Beauty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ulta Beauty compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Ulta Beauty's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Ulta Beauty's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ULTA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ulta Beauty analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Ulta Beauty</h2>
<p>With 1,385 stores at the end of fiscal 2023 and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the US. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and more than 600 individual brands. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.</p>
<h3>Ulta Beauty: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Ulta Beauty's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.88%</strong> as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Ulta Beauty's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.9%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>10.87%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Ulta Beauty's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.44%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Ulta Beauty's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.82</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ULTA

Breaking Down Ulta Beauty: 31 Analysts Share Their Views

<p>Citigroup  analyst Spiro Dounis   upgrades DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) from Neutral to Buy and raises the price target from $90 to $115.</p>


Upgrades

Citigroup Upgrades DT Midstream to Buy, Raises Price Target to $115

<p>Ratings for Piedmont Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Piedmont Lithium, revealing an average target of $12.97, a high estimate of $31.00, and a low estimate of $7.80. Highlighting a 28.42% decrease, the current average has fallen from the previous average price target of $18.12. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732190436_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Piedmont Lithium among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austin Yun</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Neutral</td>
<td>$13.50</td>
<td>-</td>
</tr>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Greg Jones</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$9.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Hayden Bairstow</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Underperform</td>
<td>$7.80</td>
<td>-</td>
</tr>
<tr>
<td>Greg Jones</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.50</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Piedmont Lithium. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Piedmont Lithium compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Piedmont Lithium's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Piedmont Lithium's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PLL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Piedmont Lithium analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Piedmont Lithium's Background</h2>
<p>Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.</p>
<h3>Piedmont Lithium's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Piedmont Lithium's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-41.3%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Piedmont Lithium's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-60.32%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Piedmont Lithium's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-5.7%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Piedmont Lithium's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-4.99%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.09</strong>, Piedmont Lithium adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Piedmont Lithium Through The Eyes Of 6 Analysts

<p>Analysts' ratings for DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $89.56, a high estimate of $115.00, and a low estimate of $74.00. Witnessing a positive shift, the current average has risen by 14.5% from the previous average price target of $78.22.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732190429_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of DT Midstream by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Mackay</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$89.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$92.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DT Midstream. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DT Midstream compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of DT Midstream's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of DT Midstream's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on DT Midstream analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind DT Midstream</h2>
<p>DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.</p>
<h3>DT Midstream: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, DT Midstream showcased positive performance, achieving a revenue growth rate of <strong>5.98%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> DT Midstream's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>35.48%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> DT Midstream's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.09%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> DT Midstream's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.0%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.65</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down DT Midstream: 9 Analysts Share Their Views

<p>Throughout the last three months, 4 analysts have evaluated UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $131.5, a high estimate of $156.00, and a low estimate of $120.00. This upward trend is evident, with the current average reflecting a 16.89% increase from the previous average price target of $112.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732190418_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive UMB Financial. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Wilczynski</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$156.00</td>
<td>-</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Benjamin Gerlinger</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$127.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UMB Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of UMB Financial's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UMB Financial's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on UMB Financial analyst ratings.</strong></a></p>
<h2>All You Need to Know About UMB Financial</h2>
<p>UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking, asset management, and health spending solutions. Its customer base includes commercial, institutional, and personal customers across the United States. The company's banking subsidiaries own and operate banking and wealth-management centers mostly throughout the Midwest and Southwest regions of the U.S. Subsidiaries of the holding company and its lead bank, UMB Bank, include mutual fund and alternative investment services groups, single-purpose companies that deal with brokerage services and insurance, and a registered investment advisory. The bank's revenue is split nearly evenly between interest income and noninterest income.</p>
<h3>UMB Financial: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> UMB Financial's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>13.47%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> UMB Financial's net margin is impressive, surpassing industry averages. With a net margin of <strong>30.13%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> UMB Financial's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.24%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> UMB Financial's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.24%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.18</strong>, UMB Financial adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UMBF

Decoding 4 Analyst Evaluations For UMB Financial

<p>Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $45.35, a high estimate of $92.00, and a low estimate of $24.00. A 23.06% drop is evident in the current average compared to the previous average price target of $58.94. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732190409_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Justin Kim</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$57.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Apellis Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Apellis Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Apellis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>All You Need to Know About Apellis Pharmaceuticals</h2>
<p>Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</p>
<h3>Key Indicators: Apellis Pharmaceuticals's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Apellis Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>78.29%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Apellis Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-29.19%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-22.91%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-6.36%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Apellis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.98</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


APLS

A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts

<p>On August 22, 2024, the Company previously guided to fiscal 2024 comparable club sales, excluding the impact of gasoline sales, at the high end of a 1% to 2% year-over-year growth range; fiscal 2024 merchandise gross margins to be approximately flat year-over-year; and fiscal 2024 adjusted EPS potentially toward the low end of a $3.75 to $4.00 range.</p>


BJ's Wholesale Club Expects FY24 Comparable Club Sales, Excluding The Impact Of Gasoline Sales, To Increase 2.3%-2.4% YoY Compared To Prior Guidance Of At The High End Of 1%-2%

<p>HC Wainwright &amp; Co.  analyst Mitchell Kapoor   reiterates Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Buy and maintains $7 price target.</p>


HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

BJ's Wholesale Club Expects Q4 FY24 Comparable Club Sales, Excluding The Impact Of Gasoline Sales, To Increase 2.5%-3.0% YoY

<p>"As we look ahead, we remain confident in our ability to drive long-term growth and shareholder value led by our continued focus on our strategic priorities," said Laura Felice, Executive Vice President, Chief Financial Officer, BJ's Wholesale Club. "We expect fourth quarter fiscal 2024 comparable club sales, excluding the impact of gasoline sales, to increase 2.5% to 3.0% year-over-year, bringing the full year fiscal 2024 growth to between 2.3% and 2.4%. We continue to expect fiscal 2024 merchandise gross margins to remain approximately flat year-over-year. Finally, we expect fourth quarter fiscal 2024 adjusted EPS to range from $0.78 to $0.88, bringing the full year fiscal 2024 range to $3.90 to $4.00."</p>


Retail Sales

BJ's Wholesale Club Expect Q4 FY24 Adjusted EPS Of $0.78-$0.88, With FY2024 Adjusted EPS Of $3.90-$4.00 Versus Prior Guidance Of $3.75-$4.00 And Consensus Of $3.84

Ensysce Biosciences GAAP EPS of -$0.55

Ensysce Biosciences regains Nasdaq compliance

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Ensysce Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ensc-stock-quote/"><strong>ENSC</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Ensysce Biosciences reported earnings per share of -55 cents. This was above the analyst estimate for EPS of -93 cents.</li><li>The company reported revenue of $305,722.</li><li>This was 23.57% worse than the analyst estimate for revenue of $400,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/06/ensc-stock-earnings-ensysce-biosciences-for-q1-of-2024/">ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Ensysce Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ensc-stock-quote/"><strong>ENSC</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Ensysce Biosciences reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -39 cents.</li><li>The company reported revenue of $181,797.</li><li>This was 39.40% worse than the analyst estimate for revenue of $300,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ensc-stock-earnings-ensysce-biosciences-for-q2-of-2024/">ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024

Ensysce Biosciences GAAP EPS of -$0.22 beats by $0.11

Ensysce wins $14M federal grant for lead pain therapy

Voxx International Corp., Trinity Biotech Plc, and Ensysce Biosciences are the 3 Penny Stocks to watch on August 29, based on&nbsp;TipRanks' Penny ...

3 Penny Stocks to Watch Now, 8/29/24

Ensysce Biosciences announces $5M concurrent offering, shares fall

Ensysce Biosciences receives non-compliance notice from Nasdaq

Ensysce Biosciences GAAP EPS of $0.07 beats by $0.24

TRIB

VOXX

Offerings

Press Releases

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Presenting at Upcoming Meetings

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Power Nickel Announces Major Copper Discovery as Gold Hits Historic High more stocks inside….

Comments

Ensysce Biosciences

Ensysce Biosciences (ENSC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga